Get started
Author

Kashif Ali

Observed name: Kashif Ali, MD
ORCID: 0009-0004-6635-0561
Observed ORCIDs: 0009-0004-6635-0561, 0009-0003-4322-2308
OpenAlex ID: A5034234212
Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study.
2023 · Makenzi Colleen Evangelist, James Edward Butrynski, et al. · Journal of Clinical Oncology · 10
PDF
ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd).
2024 · Debashish Tripathy, Kashif Ali, et al. · Journal of Clinical Oncology · 6
Biomarker testing in early-stage NSCLC: Results from the MYLUNG Consortium.
2024 · Makenzi Colleen Evangelist, James Edward Butrynski, et al. · Journal of Clinical Oncology · 4
Abstract PD18-09: ACE-Breast-03: Efficacy and safety of ARX788 in patients with HER2+ metastatic breast cancer previously treated with T-DM1
2023 · Sara Hurvitz, Kevin Kalinsky, et al. · Cancer Research · 4
Biomarker Testing Rates and Patterns in Patients With Metastatic Non–Small Cell Lung Cancer: A Prospective, Observational Study in Community Practices
2026 · Makenzi Evangelist, Bo Wang, et al. · JCO Precision Oncology · 1
PDF
Rectosigmoid Intussusception Due to a Nonmalignant Etiology: An Extremely Rare Cause of Acute Lower Gastrointestinal Bleeding in an Elderly Patient
2025 · Kashif Ali, Samra Sohail, et al. · ACG Case Reports Journal · 1
Triple Air Leak Syndrome in Cannabinoid Hyperemesis: A Diagnostic Challenge Managed Conservatively
2025 · Kashif Ali, Aresha Masood Shah, et al. · ACG Case Reports Journal
Abstract P2-10-20: ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd)
2025 · Joyce O’Shaughnessy, Kashif Ali, et al. · Clinical Cancer Research
Impact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network’s MYLUNG Consortium
2024 · Elizabeth Koselke, PharmD, BCOP, Lisa C. Kaspin-Powell, PhD, et al. · Journal of the Advanced Practitioner in Oncology
PDF
Abstract PO1-04-02: ACE-Breast-03: A phase 2 study of ARX788, a novel next-generation anti-HER antibody-drug conjugate in HER2-positive metastatic breast cancer patients previously treated with trastuzumab deruxtecan
2024 · Kashif Ali, Laila Agrawal, et al. · Cancer Research
Impact of oncology clinical pharmacist intervention on clinical trial enrollment in The U.S. Oncology Network’s MYLUNG Consortium.
2022 · Elizabeth Koselke, Shannon Hough, et al. · Journal of Clinical Oncology
Works count: 11
Citation count: 26
H-index: 4
I10-index: 1
Year
Topic
Type